 |
|
 |
 |
 |
|||
About UsOBodies is a company formed by WaikatoLink Limited, the technology transfer office of the
University of Waikato
in Hamilton, New Zealand.
Their technologies will occupy part of the monoclonal antibody market, in addition to creating new markets through the ability to utilise OBodies in situations where traditional antibodies are unsuitable (for example, where heat stability is required). Market Opportunity OBodies platform technology has applications within:
The global diagnostic and therapeutic market is worth US$95 billion. Literally thousands of commercial applications exist for OBodies high affinity proteins, and it is estimated there are over 10,000 separate antibodies used in industrial research, clinical diagnostics and therapeutic applications today.
|
 |
|||
|
||||
 |
 |
|||
